Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals

Antiviral Therapy

Volumn 20, Issue 8, 2015, Pages 865-869

  Nguyen, Linh Thuy ^a,b,f   Gray, Emma ^c,d   Dean, Jonathan ^b   Carr, Michael ^b   Connell, Jeff ^b,d   De Gascun, Cillian ^b,d   Nguyen, Lan Anh ^a   O'Leary, Aisling ^c,d   Bergin, Colm ^c,d,e   Hall, William ^a,b   Norris, Suzanne ^c,d,e  

^a Ireland Vietnam Blood Borne Virus Initiative (IVVI)   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d Irish Hepatitis C Outcomes Research Network (ICORN)   (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f Ireland Vietnam Blood Borne Virus Initiative (IVVI)   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; TELAPREVIR; VIRUS DNA; ANTIVIRUS AGENT; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS C; CLINICAL TRIAL; DNA POLYMORPHISM; FEMALE; GENE IDENTIFICATION; GENETIC VARIATION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS GENE; VIRUS MUTATION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RETREATMENT; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROTEASE INHIBITORS; RETREATMENT; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84973573737     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2964     Document Type: Article

References (23)

1. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54:96-104.
2. Moore C, Levitsky J. The current state and future prospects of chronic hepatitis C virus infection treatment. Curr Infect Dis Rep 2014; 16:413.
3. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res 2014; 105:64-71.
4. Vicenti I, Rosi A, Saladini F, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother 2012; 67:984-987.
5. Paolucci S, Fiorina L, Piralla A, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J 2012; 9:245.
6. Leggewie M, Sreenu VB, Abdelrahman T, et al. Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C. AIDS 2013; 15:2485-2488.
7. Palanisamy N, Danielsson A, Kokkula C, et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res 2013; 99:12-17.
8. Andonov A, Kadkhoda K, Osiowy C, Kaita L. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C subgenotype 1a-infected patients from Manitoba. Can J Gastroenterol 2013; 27:414-416.
9. Nishiya AS, De Almeida-Neto C, Ferreira SC, et al. HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood Donors in Sao Paulo, Brazil. PLoS ONE 2014; 9:e86413.
10. Ehret R, Neifer S, Walter H, Baumgarten A, Obermeier M. Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory. J Int AIDS Soc 2014; 17 Suppl 3:19741.
11. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
12. Berger KL, Triki I, Cartier M, et al. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 2014; 58:698-705.
13. Lenz O, Fevery B, Verbinnen T, et al. Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies. Hepatology 2013; 58:743A.
14. Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 2011; 18:608-618.
15. De Luca A, Di Giambenedetto S, Prosperi M, et al. Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3/4A inhibitors. Antivir Ther 2013; 18 Suppl 1:A47.
16. Mani N. Clinically relevant HCV drug resistance mutations figure and tables. Annals of the Forum for Collaborative HIV Research 2012; 14:1-10.
17. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012; 20:139-145.
18. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20:9633-9652.
19. Boglione L, De Nicolo A, Cardellino CS, et al. Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Clin Microbiol Infect 2015. 21:205e1-3.
20. Kieffer TL, George S. Resistance to hepatitis C virus protease inhibitors. Curr Opin Virol 2014; 8:16-21.
21. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26:487-503.
22. Larrat S, Kulkarni O, Claude JB, et al. Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients. J Clin Microbiol 2015; 53:389-397.
23. Trimoulet P, Pinson P, Papuchon J, et al. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy. Antivir Ther 2013; 18:723-727.